The US Rifaximin market gave a small but noticeable growth upwards in November and that upward momentum carried over into the first week of December. Despite this, market optimism stayed firmly in place as suppliers continued to keep the product flowing and the supply chain stayed steady. Imports from key overseas producers were running smoothly with no bumps along the way, no regulatory holdups, no shipping delays. Gastroenterology and hepatology applications kept on ticking, due to steady growth in prescriptions and the fact that reimbursement remained right on track for buyers. Most buyers simply went ahead and adhered to their usual buying schedule, rather than trying to hold off on purchases. Inventory levels were right, with none of the usual surplus worries showing up. And to top it all off, the early December activity showed the market was still strong with distributors taking a cautious approach but still managing to cover the rest of their needs. Market experts however think that Rifaximin prices will continue to go up over the next few weeks of December, and that's down to consistent sales, steady shipments coming in from the West Coast and the general feeling of optimism that's kept prices ticking upwards.
In November, the US Rifaximin market saw a slight upturn, with the upward trend continuing through the following week in December. The uptick in volume has been characterized as slow but steady, driven mainly by consistent distributor offtakes throughout the month, combined with stable and consistent flows of imported Rifaximin into the USA. The overall positive sentiment surrounding the Rifaximin market throughout November has been attributed to the fact that buyers purchased product to ensure adequate supply as they approached the end of the calendar year. This environment allowed Rifaximin pricing to strengthen modestly without triggering resistance from downstream customers.
During November, because of consistent procurements from buyers and supportive currency factors related to the imports from overseas suppliers, Rifaximin pricing increased. As the US Rifaximin market continues to be reliant on imports, buyers will continue to procure Rifaximin in the same manner as they have in previous months, without delaying purchases. All shipments of imported Rifaximin arrived on schedule without any delays or disruptions, and efficient customs clearance maintained supply continuity, so distributors were able to pass along minor cost increases to their customers while continuing to have an ongoing stable demand from their customers.
In November, the supply chain operated smoothly. The majority of the early phase of production across large offshore production locations continued at previously established rates without major delays. Shipments of Rifaximin into the US West Coast continued to be routed through California, providing predictable shipping times and a reliable flow of the product to California. Current inventory levels were maintained above the threshold of concern; thus, pricing discipline has developed as Rifaximin remains strong in its competitive marketplace. In addition, the absence of new regulatory barriers has resulted in a high degree of confidence that the Rifaximin supply chain will continue to be stable.
Rifaximin Demand in the US has remained steady and continues to grow. The demand for Rifaximin, for the treatment of gastroenterological and hepatological diseases, continues, as well as stable prescribing patterns in those areas. Rifaximin prescriptions provide a steady baseline source of consumption in both a chronic and a maintenance therapy context. The product has shown continued incremental growth in prescriptions due to unchanged reimbursement models and acceptance by Prescribers. Buyers tend to follow their planned procurement cycle for Rifaximin and purchase in quantities that match expected downstream needs.
Product’s price at the end of the first week of December is still generally stable. The trading of the Rifaximin market this week is being described as very positive by the market participants. Distributors are taking advantage of the positive anticipation that is present in the market and are taking steps to secure their year-end coverage without overextending themselves in inventory levels. With both a steady flow of imports and stable demand, prices increase incrementally with continued anticipation that prices will remain stable moving forward.
Expert market analysts predict that Rifaximin prices will increase in the weeks to come. The market will maintain a steady flow of product, and the increased expectations of demand will keep the market on an upward trajectory.
